597 related articles for article (PubMed ID: 12660312)
1. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
[TBL] [Abstract][Full Text] [Related]
2. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
4. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.
Riba J; Rodríguez-Fornells A; Barbanoj MJ
Psychopharmacology (Berl); 2002 Dec; 165(1):18-28. PubMed ID: 12474114
[TBL] [Abstract][Full Text] [Related]
5. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography.
Riba J; Anderer P; Jané F; Saletu B; Barbanoj MJ
Neuropsychobiology; 2004; 50(1):89-101. PubMed ID: 15179026
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
8. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.
Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A
Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972
[TBL] [Abstract][Full Text] [Related]
9. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers.
Riba J; Anderer P; Morte A; Urbano G; Jané F; Saletu B; Barbanoj MJ
Br J Clin Pharmacol; 2002 Jun; 53(6):613-28. PubMed ID: 12047486
[TBL] [Abstract][Full Text] [Related]
10. Identification of N,N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage.
Gambelunghe C; Aroni K; Rossi R; Moretti L; Bacci M
Biomed Chromatogr; 2008 Oct; 22(10):1056-9. PubMed ID: 18506697
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of ayahuasca administered in two repeated doses.
Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
[TBL] [Abstract][Full Text] [Related]
12. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
13. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca.
Yritia M; Riba J; Ortuño J; Ramirez A; Castillo A; Alfaro Y; de la Torre R; Barbanoj MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 779(2):271-81. PubMed ID: 12361741
[TBL] [Abstract][Full Text] [Related]
14. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage.
Pires AP; De Oliveira CD; Moura S; Dörr FA; Silva WA; Yonamine M
Phytochem Anal; 2009; 20(2):149-53. PubMed ID: 19140116
[TBL] [Abstract][Full Text] [Related]
15. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.
Riba J; Romero S; Grasa E; Mena E; Carrió I; Barbanoj MJ
Psychopharmacology (Berl); 2006 May; 186(1):93-8. PubMed ID: 16575552
[TBL] [Abstract][Full Text] [Related]
16. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
[TBL] [Abstract][Full Text] [Related]
17. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.
McKenna DJ
Pharmacol Ther; 2004 May; 102(2):111-29. PubMed ID: 15163593
[TBL] [Abstract][Full Text] [Related]
18. Ayahuasca: Pharmacology, neuroscience and therapeutic potential.
Domínguez-Clavé E; Soler J; Elices M; Pascual JC; Álvarez E; de la Fuente Revenga M; Friedlander P; Feilding A; Riba J
Brain Res Bull; 2016 Sep; 126(Pt 1):89-101. PubMed ID: 26976063
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.
Mas M; Farré M; de la Torre R; Roset PN; Ortuño J; Segura J; Camí J
J Pharmacol Exp Ther; 1999 Jul; 290(1):136-45. PubMed ID: 10381769
[TBL] [Abstract][Full Text] [Related]
20. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay.
Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A
Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
